Karine Tawagi, Assistant Professor of Clinical Medicine and Fellowship Program Director at the University of Illinois Chicago, shared on X:
“One of my favorite meetings BCANTT26 starting off with YIA awardees Dr. Aditi Gupta on how peripheral immune profiling shows potential to identify patients who will respond to EV+P future aims looking at correlation with toxicities, steroids and prior treatment .”
In another post, she added։
“Excellent panel on the changing landscape of EVP BCANTT26 impt to remember pCR doesnt necessarily OS, the survival benefit of EVP is in the context of cystectomy․
Prospective bladder preservation trials are ongoing, including EV-209, EV-309․
Incredibly important points by pt advocate John Treffert – asks to:
- expand the EVP First Bladder Preservation Community RWE
- until ongoing trial results read out, choosing surveillance should remain on EV+P under an approved protocol aligned with bladder-sparing trial arms․”
Other articles about bladder cancer on OncoDaily.
